BFCC: Pan-Baltic fracture healing project receives 3.6 million euros

Fifteen partners in the “BFCC – Baltic Fracture Competence Centre” project aim to discover opportunities for innovation in fracture healing and to support collaboration between industry and hospitals. The BFCC and 34 further finalists were ultimately approved from 282 ideas that were initially submitted in the application round of the “Interreg Baltic Sea Region Programme”. "BFCC is a model for successful cooperation between industry and hospitals," says Dr. Hinrich Habeck, Managing Director of Life Science Nord Management GmbH, the lead partner in the project application. "For the project's goal of promoting innovation in fracture healing in the best possible way, the combination and pooling of a range of strengths is the key to success."

Combining know-how in the cross-country project

Initially, therefore, a pan-Baltic cooperation platform will be established linking hospitals, industry, research institutes and networks. In the BFCC, patient data or information about treatment methods and successes can for example be recorded and analyzed in a joint fracture register across countries. Existing fracture registers, from Sweden and Denmark, will serve as a model or will be integrated (Germany, Poland, Lithuania and Estonia). In this way, the BFCC will highlight proven methods in everyday hospital treatment in fracture management and point out the potential for innovation and where innovation is needed. Building on that basis, the project will seek to implement three transnational innovation projects to test cooperation arrangements between industry and clinics in which the six participating hospitals and four companies will be involved.

Excellent project partners

With the lead partner Life Science Nord Management GmbH and 14 further project partners from the Baltic Sea region - including University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck and Stryker Trauma GmbH from the Life Science Nord Cluster - as well as 26 associated organizations, the BFCC already has an excellent basis on which to build a pan-Baltic platform für future collaboration and foster innovation in fracture management.

Further information

about the BFCC: http://www.lifesciencenord.de/aktivitaeten/projekte/bfcc-bone-fracture-competence-centre/
about the Interreg Baltic Sea Region Programme: http://www.interreg-baltic.eu 

Contact

Dr. Imke Schneemann
Life Science Nord Management
schneemann@lifesciencenord.de 
+49 431 9089 6858
www.lifesciencenord.de 

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …